Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
Chiasma hopes to be able to file its oral acromegaly therapy by year-end, and Novartis wants to shore up its MS franchise.
Senseonics best-in-class claims to be tested when blood glucose monitor goes before regulator.
The price of early stage cancer assets leaves Celgene shelling out $3.5bn in upfront payments, with no end in sight for rising valuations.
As companies retreat from M&A licensing deal valuations hit new peak.